fate stock price target

47 rows Close price at the end of the last trading day Friday 6th May 2022 of. FATE is higher by 060 from the previous closing price of 5876 on volume of 809593 shares.

Bidness Sheds Light On Stifel S Decision To Initiate Coverage On Solarcity Corp Nasdaq Scty Stock With A Buy Rating An Hot Tub Cover Business Finance Company

According to analysts consensus price target of 8722 Fate Therapeutics has a forecasted upside of 2676 from its current price of 2373.

. Amount of Analyst Coverage. Fate Therapeutics price target lowered to 75 from 125 at Truist Truist analyst Robyn Karnauskas. FATE stock price news historical charts analyst ratings and financial information from WSJ.

High Price Target. 13500 Spread Highest target. That FAT BRANDSs share price could reach 2500 by Mar 23 2023.

In terms of how Fate Therapeutics Inc fares relative to Pharmaceutical Products stocks note that its average analyst price target is higher than 145991 of that group. The average price target represents a 25640 change from the last price of 2145. The average twelve-month price target for Fate Therapeutics is 8722 with a high price target of 11600 and a low price target of 6000.

5 Wall Street analysts that have issued a 1 year FATE price target the average FATE price target is 8720 with the highest FATE stock price forecast at 11500 and the lowest FATE stock price forecast at 4500. Find real-time FATE - Fate Therapeutics Inc stock quotes company profile news and forecasts from CNN Business. Find the latest Fate Therapeutics Inc FATE stock price forecast 12-month price target predictions and analyst recommendations.

25640 Upside Based on 8 Wall Street analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is 7643 with a high forecast of 11500 and a low forecast of 4500. FATE were skyrocketing 473 higher as of 1143 am.

Fate Therapeutics has only been the subject of 3 research reports in the past 90 days. The average price target is 000 with a high estimate of 000 and a low estimate of 000. FATE has a greater upside potential average analyst target price relative to current price than 149379 of stocks in the mid market cap category.

In-depth view of key statistics and finances for FATE THERAPEUTICS INC. 128 rows The average price target is 8722 with a high forecast of 000 and a low forecast. Shares of Fate Therapeutics NASDAQ.

Find the latest Fate Therapeutics Inc. HC Wainwright dropped their price target on Fate Therapeutics from 12200 to 11500 and set a buy rating on the stock in a research report on Friday March 4th. Evolution of the average Target Price on FATE THERAPEUTICS INC.

The companys stock tumbled this summer in response to clinical-trial results. Over the past year the SP 500 has risen 2298 while FATE is lower by -3689. Fate Therapeutics Inc FATE stock has gained 102 while the SP 500 is lower by -166 as of 130 PM on Monday Dec 20.

FATE stock discussion in Yahoo Finances forum. 1 Wall Street analyst that have issued a 1 year FAT price target the average FAT price target is 2500 with the highest FAT stock price forecast at 2500 and the lowest FAT stock price forecast at 2500The Wall Street analyst predicted. 9189 Spread Average Target.

The huge jump came after the biotech announced positive interim data from an early-stage. 1y Target Est 8626 Fair Value is the appropriate price for the shares of a company based on its earnings and growth rate also interpreted as when PE Ratio Growth Rate. Currency In USD.

View the latest Fate Therapeutics Inc. Find out what this means to you and get the rest of the rankings on FATE. With a target price of 8500 there is potential for a 214001 increase which would mean more than doubling the current price of 2707 for Fate Therapeutics Inc.

FATE on MSN Money. Price Target UpsideDownside. Based on analysts offering 12 month price targets for FATE in the last 3 months.

The average price target for FATE is 80214 and analysts rate the stock as a Strong Buy Wall Street analysts are rating FATE a Strong Buy today. According to the issued ratings of 9 analysts in the last year the consensus rating for Fate Therapeutics stock is Buy based on the current 2 hold ratings and 7 buy ratings for FATE. The consensus price target among Wall Street analysts represents a 101 premium over Fate Therapeutics recent price.

Our community identified positive and negative aspects for.

3 Strong Buy Stocks Under 10 That Are Poised To Break Out Nasdaq